Fares Noujaim, an executive vice chairman at Bank of America has left the company abruptly.» Read More
One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!
The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.
New evidence of the power of the multi-billion dollar impotence drugs. A study just out in the peer-reviewed "British Medical Journal" says that the elderly are having sex more often, possibly due to the popular pills for erectile dysfunction.
Some traders are also turning bullish. John Mendelson of the Stanford Group issued a buy signal late in the day; traders tell me it was his 3rd buy signal in 5 years, and the prior two calls were very good.
In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.
After hours Morgan Stanley recommended investors buy Lehman Brothers stock and set a price target of $31. What's the "Word on the Street?"
It was an ugly first half for the stock market and now that the goal posts have been moved for the economic recovery, expect a rough game in the second half.
One sector in particular is up despite a previous beat-down. Is this a sign?
As growth in Western economies slows, investors searching for attractive stocks should look to companies that sell to more resilient emerging markets, James Bevan, chief investment officer at CCLA Investment Management, told CNBC Europe Tuesday.
Walgreen posted a 2 percent increase in quarterly profit as sales were muted by a weak U.S. economy and slowing growth in prescription drug sales.
As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...
Stocks closed lower again on Wednesday. For a time, the Dow traded below the 12,000 mark for the first time since mid-March. What's the "Word on the Street?"
Stocks closed lower Wednesday, led by financial and auto stocks after worrisome results from Morgan Stanley, CarMax and FedEx. Regional banks also took a hit after Fifth Third cut its dividend.
Stocks declined Wednesday, led by financials, after worrisome results from Morgan Stanley and a dismal outlook from FedEx. The Dow briefly slipped below 12,000 -- the first time that's happened since March 18, when the market was reeling from the collapse of Bear Stearns.
Stocks rallied to the finish Friday, led by financials and techs, as a tame core-inflation reading and lower oil helped the market end a chaotic week on a high note.
Markets in the last hour: A strong dollar and lower oil helped stocks today, enough to eke out a small gain of 0.8 percent for the Dow for the week (the only major index that was up this week
Stocks regained lost ground heading into the final hour of trade, with lower oil boosting financials and a host of other beaten-down sectors as Wall Street bid to finish a seesaw week slightly higher.
Stocks continued a solid rally Friday, boosted by falling oil prices and investors who swooped in to snatch up battered financial stocks.
It never ceases to amaze me who reads Pharma's Market. Like the Stanford University professor who wrote to set the record straight regarding my coverage from ASCO of the brain cancer vaccine from Pfizer and Avant.
Pfizer shares continue to trade at new nearly 11-year lows over concerns the dividend might get cut, in addition to the lack of anything visible to replace Lipitor when it goes generic in a couple years or so. But on two of the op-ed pages in Wednesday's "Wall Street Journal" Pfizer got a plug.